4-Chloro-2,6-bis(1-methylethyl)benzenamine hydrochloride | 404844-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-2,6-bis(1-methylethyl)benzenamine hydrochloride
• 英文别名: 4-chloro-2,6-di(propan-2-yl)aniline;hydrochloride
• CAS: 404844-12-8
• 化学式: C12H19Cl2N
• 分子量: 248.19
• InChiKey: ZRDPXADRNVRMGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.59
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• DIARYLSULFONYLUREA BINDING PROTEINS
  申请人：——

  公开号：US20020034764A1

  公开（公告）日：2002-03-21

  The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.

  本发明涉及到二芳基磺酰脲结合蛋白（DBPs）的鉴定，作为抑制炎症介质释放的治疗靶点，例如白细胞介素IL-1和IL-1β的药物。
• Diarylsulfonylurea binding proteins
  申请人：Pfizer Inc.

  公开号：US20030027217A1

  公开（公告）日：2003-02-06

  The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.

  本发明涉及日萘磺酰脲结合蛋白（DBPs）的鉴定，作为抑制释放炎症介质如白细胞介素IL-1和IL-1β的药物治疗靶点。
• COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE
  申请人：Pfizer Products Inc.

  公开号：EP1214087A1

  公开（公告）日：2002-06-19
• [EN] COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS<br/>[FR] TRAITEMENT COMBINE AU MOYEN DE IL-1RA ET DE COMPOSES DE DIARYLSULFONYLUREE
  申请人：PFIZER PROD INC

  公开号：WO2001019390A1

  公开（公告）日：2001-03-22

  The invention relates to methods and compositions for treating and preventing interleukin 1 (IL-1) mediated disease states. The methods and compositions use an interleukin 1 receptor antagonist (IL-1ra) polypeptide or variant thereof in combination with a non-steroidal IL-1 processing and release inhibiting agent.